Hedy Lee Kindler

Hedy Lee Kindler's AcademicInfluence.com Rankings

Hedy Lee Kindler

Philosophy

#8414

World Rank

#11794

Historical Rank

Logic

#5453

World Rank

#6857

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Hedy Lee Kindler's Degrees

Doctorate Medicine University of Chicago
Masters Health Studies University of Chicago

Why Is Hedy Lee Kindler Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hedy Lee Kindler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer (2016) (2632)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (2019) (1152)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. (2020) (873)
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010) (790)
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. (2005) (473)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. (2007) (410)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (2015) (385)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. (2009) (381)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. (2011) (362)
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. (1999) (360)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. (2016) (353)
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers (2007) (351)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma. (2018) (340)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. (2017) (328)
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. (2005) (315)
Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design (2013) (304)
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (267)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B (2005) (254)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer (2009) (254)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. (2003) (254)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB (2007) (249)
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. (2018) (207)
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. (2012) (205)
Malignant pleural mesothelioma. (2009) (204)
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. (2008) (202)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. (2006) (189)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. (2020) (184)
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma (2016) (161)
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. (2015) (159)
Malignant pleural mesothelioma: an update on biomarkers and treatment. (2009) (152)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. (2014) (145)
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma (2016) (142)
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. (2012) (140)
Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors (2004) (138)
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time (2004) (126)
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. (2002) (125)
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. (2018) (123)
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. (2018) (122)
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) (2019) (116)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 (2010) (116)
Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial (2018) (114)
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma (2016) (112)
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma (2016) (112)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. (2015) (110)
Phase II study of flavopiridol in patients with advanced colorectal cancer. (2003) (108)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma (2008) (107)
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. (2008) (100)
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. (2020) (97)
A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303 (2011) (94)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) (2007) (94)
Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium (2008) (93)
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (2004) (92)
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). (2012) (91)
Metastatic colorectal cancer (2001) (91)
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. (2012) (90)
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium (2012) (87)
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma (2018) (87)
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies (2009) (86)
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy (2019) (85)
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma (2011) (85)
Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 (2019) (85)
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) (2013) (84)
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. (2001) (81)
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). (2001) (81)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors (2016) (80)
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (2009) (79)
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). (2010) (79)
Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors (2004) (78)
Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. (2011) (78)
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. (2004) (76)
Tumor genome analysis includes germline genome: Are we ready for surprises? (2014) (75)
Update on malignant pleural mesothelioma. (2011) (75)
A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. (2004) (72)
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation (2018) (71)
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients (2013) (70)
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab (2006) (70)
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma (1999) (70)
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. (2004) (69)
Malignant pleural mesothelioma (2000) (68)
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma (2018) (68)
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) (2014) (67)
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. (2007) (66)
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. (2006) (66)
Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium (2007) (65)
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma (2008) (64)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors (2020) (63)
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). (2012) (63)
Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors (2018) (63)
Systemic Treatments for Mesothelioma: Standard and Novel (2008) (63)
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer (2009) (62)
Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. (2006) (61)
Weekly, high‐dose paclitaxel in advanced lung carcinoma (2003) (60)
Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor (2013) (59)
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. (2019) (59)
Phase I clinical and pharmacokinetic study of protein kinase C-α antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer (2002) (58)
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer (2017) (57)
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. (2016) (57)
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. (2006) (56)
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers (2005) (55)
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma (2014) (54)
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. (2012) (54)
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). (2015) (54)
A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors (2004) (53)
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report (2012) (53)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. (2021) (52)
Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. (2009) (52)
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. (1997) (51)
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer (2013) (51)
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. (2002) (51)
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. (2004) (49)
Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. (2004) (49)
Computerized segmentation and measurement of malignant pleural mesothelioma. (2010) (48)
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium (2012) (48)
The role of gemcitabine in the treatment of malignant mesothelioma. (2002) (48)
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma (2019) (47)
OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis (2018) (47)
Variability in mesothelioma tumor response classification. (2006) (46)
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. (2008) (46)
Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). (2017) (46)
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. (2008) (46)
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) (2018) (45)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms (2020) (44)
Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance) (2018) (44)
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). (2006) (44)
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. (2016) (43)
Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). (2014) (43)
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study. (2013) (43)
Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine: A Phase II Trial of the University of Chicago Phase II Consortium (2008) (42)
Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) (2005) (41)
Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies (2004) (41)
A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma (2011) (41)
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) (2017) (41)
Peritoneal mesothelioma: the site of origin matters. (2013) (39)
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. (2004) (39)
A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). (2010) (39)
PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. (2020) (38)
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. (2005) (38)
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). (2016) (38)
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. (2020) (38)
Phase I/II Trial of Gefitinib and Oxaliplatin in Patients With Advanced Colorectal Cancer (2005) (37)
A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree Carcinoma (2004) (37)
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. (2017) (37)
Pancreatic cancer: An update (2007) (36)
Immunogenicity of biotinylated hapten-avidin complexes. (1984) (36)
Personalized colon cancer care in 2010. (2011) (36)
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. (2013) (36)
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial (2021) (35)
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease. (2020) (35)
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma (2016) (35)
A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). (2004) (35)
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) (2008) (34)
A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma (2007) (34)
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. (2021) (33)
Front-line therapy of advanced pancreatic cancer. (2005) (33)
A Glimmer of Hope for Pancreatic Cancer. (2018) (33)
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. (2013) (33)
Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307) (2007) (33)
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma (2013) (33)
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). (2015) (32)
A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). (2009) (31)
Antiangiogenic therapies for mesothelioma. (2005) (31)
The pemetrexed/gemcitabine combination in pancreatic cancer (2002) (31)
OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis (2017) (31)
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. (2012) (31)
OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma (2017) (31)
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). (2014) (30)
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial (2011) (30)
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors (1997) (29)
Disease volumes as a marker for patient response in malignant pleural mesothelioma. (2013) (29)
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. (2012) (28)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases (2020) (28)
A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation. (2020) (28)
Current state and future directions of pleural mesothelioma imaging. (2008) (28)
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. (2000) (27)
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study (2018) (26)
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab (2015) (26)
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. (2005) (26)
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors (2017) (25)
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. (2020) (25)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases (2020) (25)
Chemotherapy for advanced pancreatic cancer: Past, present, and future (2005) (25)
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. (1998) (25)
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. (2002) (24)
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303) (2012) (24)
A UGT1A1 genotype‐guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies (2019) (24)
Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma (2001) (23)
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). (2012) (23)
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma (2016) (23)
A Phase II Prospective Multi-Institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903 (2009) (23)
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. (2015) (22)
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. (2012) (22)
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. (2015) (22)
Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study (2008) (22)
Robust data: the essential foundation of a revised staging system for pleural mesothelioma. (2012) (21)
Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma (2012) (21)
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma (2013) (21)
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. (2014) (21)
The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations (2020) (21)
Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). (2018) (21)
A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. (2006) (21)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib (2019) (21)
The Chicago Consensus on Peritoneal Surface Malignancies: Standards (2020) (21)
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors (2020) (21)
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance) (2018) (20)
Production of a fibronectin-associated lymphokine by cloned mouse T cells. (1988) (20)
The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms (2020) (20)
A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM) (2007) (20)
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. (2015) (20)
Oral fluoropyrimidine treatment of colorectal cancer. (2001) (20)
A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy (2007) (20)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors (2020) (19)
Considering the role of radiation therapy for gastrointestinal stromal tumor (2014) (19)
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. (2020) (19)
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. (2020) (19)
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase (2000) (18)
A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. (2013) (18)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma (2020) (18)
A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303 (2007) (18)
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. (2016) (18)
Variability of tumor area measurements for response assessment in malignant pleural mesothelioma. (2013) (17)
Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium. (2011) (17)
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer (2005) (17)
POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). (2016) (17)
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2022) (17)
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance) (2018) (17)
Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. (2010) (17)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms (2020) (16)
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial (2019) (16)
Predictive Biomarkers and Personalized Medicine Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer : Results from CALGB 80303 ( Alliance ) (2013) (16)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. (2019) (16)
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. (2001) (16)
Sphingosine Kinase 1 Is Required for Mesothelioma Cell Proliferation: Role of Histone Acetylation (2012) (16)
A Phase II Study of a Human Anti-PDGFRα Monoclonal Antibody (Olaratumab, IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors. (2017) (16)
Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). (2011) (16)
POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy. (2015) (16)
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma (2019) (15)
The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms (2020) (15)
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. (2011) (15)
A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). (2016) (14)
CRS‐207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial: 208O_PR (2016) (14)
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors (2021) (14)
The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. (2018) (14)
Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. (2012) (14)
Radiologic-pathologic correlation of mesothelioma tumor volume. (2015) (14)
Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC). (2015) (13)
P-403 Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107) (2005) (13)
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. (2011) (12)
A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): An updated analysis. (2006) (12)
T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma. (2014) (12)
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma (2019) (12)
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy (2020) (12)
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism (2011) (12)
Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). (2018) (12)
A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). (2012) (12)
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases (2020) (12)
Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations. (2022) (12)
Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). (2019) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
6502 A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts) (2009) (11)
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289). (2018) (11)
Protein kinase C beta in malignant pleural mesothelioma (2008) (11)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. (2019) (11)
A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903 (2007) (11)
A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). (2004) (11)
Toward personalized treatment for gastroesophageal adenocarcinoma (GEC): Strategies to address tumor heterogeneity—PANGEA. (2014) (11)
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation (2018) (11)
Pemetrexed in pancreatic cancer. (2002) (11)
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study (2018) (11)
Surgery for mesothelioma? The debate continues. (2011) (11)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors (2020) (11)
PreoperativeModified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A 021101 (2019) (11)
Genetic variation determines VEGF-A plasma levels in cancer patients (2018) (10)
MARS: a sense of perspective and an inconvenient truth. (2013) (10)
Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904 (2008) (10)
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. (2018) (10)
The clinical development of paclitaxel and the paclitaxel/carboplatin combination. (1998) (10)
Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma. (2014) (10)
The Vulnerable Elders Survey‐13 Predicts Mortality in Older Adults with Later‐Stage Colorectal Cancer Receiving Chemotherapy: A Prospective Pilot Study (2013) (9)
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma (2018) (9)
Pemetrexed in patients with gastrointestinal carcinoma. (2002) (9)
Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. (2019) (9)
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) (2018) (9)
The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma (2020) (9)
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma (2007) (9)
Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC) (2005) (9)
A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM). (2009) (9)
211 Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307 (2006) (9)
An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial (2005) (8)
Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC). (2013) (8)
A multi-center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine (2004) (8)
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). (2010) (8)
Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium. (2011) (8)
Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials (2017) (8)
Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older. (2011) (8)
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms (2020) (8)
Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance) (2022) (8)
Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance). (2017) (7)
Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM). (2014) (7)
A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with unresectable or metastatic pancreatic cancer (PC). (2006) (7)
Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). (2015) (7)
Peri-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study. (2016) (7)
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. (2022) (7)
ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium. (2015) (7)
280 Updated results of the phase I study of SS1(dsFv)PE38 for targeted therapy of mesothelin expressing cancers (2004) (7)
In focus: advanced pancreatic cancer. (2005) (7)
Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). (2011) (7)
Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T (2019) (6)
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance) (2019) (6)
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). (2011) (6)
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. (2021) (6)
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium (2004) (6)
American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance). (2017) (6)
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. (2010) (6)
The emerging role of pemetrexed for the treatment of malignant mesothelioma. (2004) (6)
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin for targeted therapy of mesothelin expressing mesotheliomas, ovarian and pancreatic cancer (2007) (6)
Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289). (2020) (6)
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance) (2021) (6)
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors (2021) (6)
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). (2020) (6)
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium (2010) (6)
Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. (2014) (6)
A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM). (2019) (6)
Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance). (2017) (6)
Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens (2021) (5)
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM) (2015) (5)
Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial. (2017) (5)
Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients (pts) with untreated malignant mesothelioma. (2010) (5)
Peritoneal Mesothelioma: The Site of Origin Matters (2013) (5)
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing (2019) (5)
COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy. (2014) (5)
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis. (2012) (5)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. (2019) (5)
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies. (2017) (5)
A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. (2020) (5)
SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors. (2020) (5)
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). (2012) (4)
FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC). (2015) (4)
The Chicago Consensus on peritoneal surface malignancies: Standards (2020) (4)
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies (2022) (4)
Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): Results of phase I study of SS1(dsFv)PE38 (SS1P) (2004) (4)
Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. (1997) (4)
Mesothelioma: Are we making progress? (2002) (4)
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). (2011) (4)
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (4)
The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review (2022) (4)
The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors (2020) (4)
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma (2012) (4)
A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma (2013) (4)
A New Direction for Pancreatic Cancer Treatment: FOLFIRINOX in Context. (2012) (4)
Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM). (2011) (4)
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance) (2020) (4)
The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations (2020) (3)
Immune escape correlates with an inflamed phenotype in malignant mesothelioma. (2015) (3)
Small cell lung cancer and other thoracic malignancies (2012) (3)
Peri-operative modified FOLFIRINOX in resectable pancreatic cancer: A pilot study. (2016) (3)
388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors (2010) (3)
Phase II trial of alimta plus gemzar administered every 21 days in patients with advanced pancreatic cancer (2001) (3)
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. (2012) (3)
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses. (2020) (3)
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639–1645 (2006) (3)
SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma (2020) (3)
Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101. (2006) (3)
Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): Results of phase I study of SS1(dsFv)PE38 (SS1P). (2004) (3)
P2.06-029 Pilot Window-Of-Opportunity Study of Pembrolizumab in Patients with Resectable Malignant Pleural Mesothelioma (MPM): Topic: Mesothelioma and SCLC (2017) (2)
Heritable interleukin-17F (IL17F) gene variation and overall survival (OS) in pancreatic cancer patients (pts): Results from a genome-wide association study (GWAS) in CALGB 80303. (2016) (2)
Development of response criteria for mesothelioma based on a mathematical model (2005) (2)
Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. (2020) (2)
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels (2022) (2)
1074TiPRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TREMELIMUMAB FOR SECOND-LINE AND THIRD-LINE TREATMENT OF UNRESECTABLE PLEURAL OR PERITONEAL MESOTHELIOMA. (2014) (2)
A Multi-Center Phase II Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody Amatuximab in Combination with Chemotherapy for Frontline Therapy of Malignant Pleural Mesothelioma: Updated Clinical Outcomes and Correlative Studies (2012) (2)
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients (2020) (2)
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma (2019) (2)
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. (2016) (2)
Clinical Trials of the Eniluracil/5-Fluorouracil Combination (2003) (2)
P1.06-04 Deep Learning-Based Segmentation of Mesothelioma on CT Scans: Application to Patient Scans Exhibiting Pleural Effusion (2019) (2)
The Cancer and Leukemia Group B Respiratory Committee (2006) (2)
Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC). (2020) (2)
Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC). (2015) (2)
174 Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM) (2005) (2)
Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer (2005) (2)
390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis (2004) (2)
Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer (2018) (2)
CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). (2016) (2)
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance) (2021) (2)
A dose-escalation study of the quinoxaline antitumor agent R(+)XK469 (XK) in patients with refractory solid tumors (2004) (2)
A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM) (2005) (2)
The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors (2020) (1)
Leptomeningeal Carcinomatosis from Pancreatic Cancer Associated With Germline BRCA Mutations: Case Reports and Review of the Literature (2016) (1)
Role of c-MET in lung cancer, malignant mesothelioma, and head and neck cancer. (2004) (1)
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
1220TiPMULTI-ARM, NONRANDOMIZED, OPEN-LABEL PHASE IB STUDY TO EVALUATE FP1039/GSK3052230 WITH CHEMOTHERAPY IN NSCLC AND MPM WITH DEREGULATED FGF PATHWAY SIGNALING. (2014) (1)
E-44. Systemic therapy for mesothelioma: Old and new (2003) (1)
Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. (2020) (1)
Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer (2022) (1)
SU‐E‐J‐96: Prognostic Value of Automatically Segmented Lung Volumes during Chemotherapy for Patients with Mesothelioma (2011) (1)
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001). (2023) (1)
POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial. (2021) (1)
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance) (2021) (1)
Phase II trial of anti-transforming growth factor-beta (TGFß) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM). (2012) (1)
SO-3 Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial (2020) (1)
Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140) (2016) (1)
Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA). (2019) (1)
Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). (2020) (1)
Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma. (2013) (1)
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC). (2012) (1)
P-620 An update of pemetrexed (P) plus gemcitabine (G) asfront-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial (2005) (1)
Management of Patients With Pancreatic Cancer Using the "Right Track" Model. (2023) (1)
Understanding the new therapeutic options for mesothelioma. (2021) (1)
Systemic Therapy for Mesothelioma: Turning the Corner. (2021) (1)
O-077 Gemcitabine/cisplatin plus bevacizumab or placebo in advanced malignant mesothelioma: A multi-center, double-blind placebo-controlled, randomized phase II trial (2005) (1)
A multi-center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine. (2004) (1)
1616OMulticenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM) (2017) (1)
1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer (2021) (1)
POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
P3.03-036 Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance):Topic: Mesothelioma Clinical (2017) (1)
1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial (2020) (1)
POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC). (2020) (1)
Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm). (2020) (1)
P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma: Topic: Mesothelioma and SCLC (2017) (1)
Reply to K. Masuda et al. (2019) (0)
Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma (2023) (0)
APhase I Trial to Determine the Safety,Tolerability, andMaximum Tolerated Dose of Deforolimus in Patients with AdvancedMalignancies (2009) (0)
Overview of the IASLC Mesothelioma workshop 2004 (2005) (0)
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance) (2022) (0)
A dose-escalation study of the quinoxaline antitumor agent R(+)XK469 (XK) in patients with refractory solid tumors. (2004) (0)
Malignant pleural mesothelioma: Inter-observer variability in the assessment of tumor response classification. (2004) (0)
SU‐E‐J‐93: Perfusion CT and Tumor Response for Patients with Mesothelioma (2011) (0)
Radiographic sarcopenia measurements to predict overall survival in patients with resectable pancreatic adenocarcinoma undergoing neoadjuvant chemotherapy. (2016) (0)
Pathway in Malignant Pleural Mesothelioma Functional Analysis of c-Met / Hepatocyte Growth Factor (2005) (0)
OA03.07 Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study (2021) (0)
P2.06-12 Dysphagia in Patients with Malignant Pleural Mesothelioma (MPM) (2019) (0)
A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. (2022) (0)
Abstract 2341: Functional analysis of paxillin mutations identified in lung cancer and malignant mesothelioma: Implications for cell migration/motility (2011) (0)
A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients. (2018) (0)
P-429 Mathematical modeling of mesothelioma growth suggestsalternate response criteria (2005) (0)
Abstract 3388: Genetic prediction of VEGF-A plasma levels in cancer patients (2016) (0)
A Phase I/II Trial of Stereotactic Body Radiation Therapy for Unresectable Pancreatic Cancer Using Ablative (BED100) Doses (2018) (0)
P1-132: Phase II study of erlotinib plus bevacizumab in patients with previously treated malignant pleural mesothelioma (2007) (0)
1298P Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation (2022) (0)
Association between ECOG PS, age, and components of the Comprehensive Geriatric Assessment (CGA) in an elderly colorectal cancer (CRC) cohort. (2009) (0)
Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors. (2013) (0)
Validation of the CALGB and EORTC Prognostic Models for Mesothelioma based on multiple CALGB Trials (Alliance) (2013) (0)
FP07.05 DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial (2021) (0)
review Current treatment options and biology of peritoneal mesothelioma: meeting summary of the ﬁrst NIH peritoneal mesothelioma conference (2006) (0)
Oral Abstracts (2011) (0)
Activated c-Met receptor tyrosine kinase: A novel molecular therapeutic target for the treatment of malignant pleural mesothelioma (2005) (0)
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA (2022) (0)
SU-F-207-06: CT-Based Assessment of Tumor Volume in Malignant Pleural Mesothelioma (2015) (0)
Abstract 5350: Single cell RNA-seq reveals transcriptionally distinct subpopulations within patient-derived pancreatic cancer organoids (2018) (0)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial (2019) (0)
OA12.01 Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma (2021) (0)
Erratum: A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma (American Journal of Clinical Oncology (December 2004) 27, 6 (505-509)) (2005) (0)
515 CRS-207, a mesothelin-targeted immunotherapy, in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM) (2015) (0)
1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer (2021) (0)
EP07.01-013 Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma (2022) (0)
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
WE‐C‐I‐609‐04: Observer Evaluation of Semi‐Automated Mesothelioma Measurements (2005) (0)
Quality of life in patients undergoing pleurectomy and decortication for malignant pleural mesothelioma. (2016) (0)
Blood-based early detection of malignant mesothelioma (2009) (0)
Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consor (2018) (0)
Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA. (2017) (0)
Reply to D. de Fonseka et al. (2018) (0)
219 The role of c-Met in mesothelioma (2006) (0)
Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies. (2018) (0)
6604 POSTER Updated Survival and Genomic Analysis of a Phase II Trial of Temsirolimus in Advanced Neuroendocrine Carcinomas (2011) (0)
87 Mesothelin-targeted immunotherapy CRS-207 plus chemotherapy as treatment for malignant pleural mesothelioma (MPM) (2016) (0)
Abstract 4272: Organoids and patient-derived tumor xenograft of pancreatic adenocarcinoma share morphological and genetic features with the primary tumor (2016) (0)
Abstract CT217: POLO: Homologous recombination repair gene mutations (HRRm) in metastatic pancreatic cancer (mPaC) tumors (2020) (0)
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. (2023) (0)
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance). (2018) (0)
Toxicity and Efficacy of Stereotactic Body Radiotherapy plus Nivolumab with Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors (2020) (0)
Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies (2022) (0)
An Update on Biomarkers and Treatment (2015) (0)
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response (2020) (0)
Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) muta (2023) (0)
P-265TUMOUR VOLUME: AN IMPORTANT PREDICTOR OF SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA (2015) (0)
Tumor volume is an independent predictor of survival in patients with malignant pleural mesothelioma (2015) (0)
Maintenance Therapy With PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer (2019) (0)
Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumors (2018) (0)
MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer (2021) (0)
Pemetrexed: A Viewpoint by Hedy L. Kindler (2003) (0)
Blood-Based Early Detection of Malignant Mesothelioma. Authors' reply (2009) (0)
A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). (2006) (0)
P-105 POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer (2021) (0)
6588 POSTER Phase 3 Dose Selection for Ganitumab (AMG 479) in Pancreatic Cancer Based on Clinical Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Assessments (2011) (0)
25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303. (2013) (0)
Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma. (2023) (0)
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress). (2021) (0)
Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM). (2016) (0)
224 Molecular targeting of malignant pleural mesothelioma by c-Met and ROS modulation (2006) (0)
Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer (2022) (0)
TITLE: Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors AUTHOR AND AFFILIATIONS: (2018) (0)
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance). (2015) (0)
Genetic variation determines VEGF-A plasma levels in cancer patients (2018) (0)
Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer (2023) (0)
Dose-Escalating S tudy o f C apecitabine P lus G emcitabine Combination T herapy i n P atients W ith A dvanced C ancer (2002) (0)
Abstract LB-124: RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma (2011) (0)
Frequency of incidental pathogenic and likely pathogenic germline variants detected via tumor-only mesothelioma genomic profiling (2022) (0)
Malignant pleural mesothelioma: Inter-observer variability in the assessment of tumor response classification (2004) (0)
Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer 1 (2002) (0)
S94 Exceptional Responders to Immunotherapy in Pancreatic Cancer: A Multi-Institutional Case Series (2021) (0)
Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study #80303 (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hedy Lee Kindler?

Hedy Lee Kindler is affiliated with the following schools:

New York Medical College
Aalborg University
MD Anderson Cancer Center
Riken
Tel Aviv University
University of Chicago
Hyogo College of Medicine
Duke University